<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025558</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068973</org_study_id>
    <secondary_id>P30CA016087</secondary_id>
    <secondary_id>NYU-0006H</secondary_id>
    <secondary_id>NCI-G01-2022</secondary_id>
    <nct_id>NCT00025558</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer</brief_title>
  <official_title>Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining temozolomide, thiotepa, and&#xD;
      carboplatin followed by peripheral stem cell transplantation or bone marrow transplantation&#xD;
      in treating patients who have brain cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of temozolomide in combination with thiotepa and&#xD;
           carboplatin followed by autologous peripheral blood stem cell or bone marrow&#xD;
           transplantation in patients with recurrent high-grade brain tumors with minimal residual&#xD;
           disease or newly-diagnosed malignant glioma with minimal residual disease following&#xD;
           irradiation.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of temozolomide.&#xD;
&#xD;
      Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 3 consecutive days.&#xD;
      After the third dose of G-CSF, patients undergo leukapheresis to collect peripheral blood&#xD;
      stem cells (PBSC). Patients who do not have adequate PBSC may undergo bone marrow harvest.&#xD;
&#xD;
      Patients then receive oral temozolomide every 12 hours on days -10 to -6 and thiotepa IV over&#xD;
      3 hours and carboplatin IV over 4 hours on days -5 to -3.&#xD;
&#xD;
      PBSC or bone marrow are reinfused on day 0. Beginning on day 1, patients receive G-CSF SC or&#xD;
      IV until blood counts recover.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at day 42, at 3 months, every 3 months for 2 years, every 4 months for&#xD;
      1 year, every 6 months for 1 year, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following malignant brain tumors:&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Medulloblastoma&#xD;
&#xD;
               -  High-grade ependymoma&#xD;
&#xD;
               -  Germ cell tumors&#xD;
&#xD;
               -  Pineoblastoma&#xD;
&#xD;
               -  Other primitive neuroectodermal tumors&#xD;
&#xD;
          -  Recurrent disease or resistant to conventional therapy (e.g., surgery, radiotherapy,&#xD;
             or standard chemotherapy)&#xD;
&#xD;
               -  No prior myeloablative doses of thiotepa OR&#xD;
&#xD;
          -  Newly diagnosed malignant glioma with minimal residual disease after prior&#xD;
             radiotherapy&#xD;
&#xD;
               -  Minimal residual disease is defined as tumor with maximum diameter of less than&#xD;
                  1.5 cm by MRI and no corticosteroid dependency&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 1 to under 50&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  Lansky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT/SGPT less than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase less than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
          -  BUN less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction greater than 50% OR&#xD;
&#xD;
          -  Shortening fraction greater than 27%&#xD;
&#xD;
          -  No evidence of myocardial ischemia on EKG if over 40 years of age&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No AIDS-related illness&#xD;
&#xD;
          -  No frequent vomiting or medical condition that would preclude oral medication (e.g.,&#xD;
             partial bowel obstruction)&#xD;
&#xD;
          -  No other malignancy within the past 2 years except surgically cured carcinoma in situ&#xD;
             of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior biologic therapy or immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 6 weeks since prior brachytherapy or radiosurgery&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon L. Gardner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 25, 2011</last_update_submitted>
  <last_update_submitted_qc>March 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2011</last_update_posted>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult central nervous system germ cell tumor</keyword>
  <keyword>adult pineoblastoma</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult supratentorial primitive neuroectodermal tumor (PNET)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

